Zoely Does Not Cause Clinically Significant Weight Gain
Based on the available evidence, Zoely (nomegestrol acetate/17β-estradiol) causes no or minimal weight gain and can be confidently prescribed without concern for this side effect. 1
Evidence-Based Assessment
Direct Evidence on Zoely
The most relevant research specifically examining Zoely demonstrates that this contraceptive formulation is characterized by "no or minimal weight gain" in clinical trials 1. This finding is particularly important because Zoely was specifically studied in overweight and obese patients, where it maintained high efficacy without causing significant weight increases 1.
Supporting Evidence from Combined Hormonal Contraceptives
The broader evidence base strongly supports weight neutrality for combined hormonal contraceptives:
Population-level data confirms no causal relationship: At the population scale, there is no evidence that estrogen-progestin contraception causes weight gain 2
Placebo-controlled trials show weight neutrality: High-quality Cochrane systematic reviews of combined oral contraceptives found no evidence supporting a causal association between combination contraceptives and weight change when compared to placebo 3
The perception exceeds reality: While weight gain is often considered a side effect and many women believe an association exists, a causal relationship has not been established 3
Why Zoely May Be Particularly Weight-Neutral
Zoely's unique formulation offers theoretical advantages:
Natural estradiol instead of ethinyl estradiol: Zoely contains 17β-estradiol (1.5 mg), which is structurally identical to endogenous estrogen, potentially offering better tolerability than synthetic ethinyl estradiol 2
Selective progestin activity: Nomegestrol acetate has greater specificity for progesterone receptors, minimizing androgenic, estrogenic, and glucocorticoid effects that could theoretically influence weight 4
Clinical Context and Counseling
What Patients May Experience
Any perceived weight changes with Zoely are likely due to:
- Fluid retention rather than fat accumulation (mediated by estrogenic stimulation of the renin-angiotensin-aldosterone system) 5
- Natural age-related weight trajectories that coincidentally occur during contraceptive use 5
- Nocebo effect from pre-existing beliefs about contraceptive-related weight gain 5
Contrast with Other Methods
It's important to distinguish Zoely from methods that DO cause weight gain:
- Depot medroxyprogesterone acetate (DMPA) is the only contraceptive with verified clinical risk for significant weight gain through fat mass accumulation 6, 5
- Injectable DMPA can cause weight gain particularly in obese adolescents 2
Practical Recommendations
For patients concerned about weight:
- Reassure them that Zoely is weight-neutral based on clinical trial evidence
- Explain that any minor fluctuations are typically fluid-related and temporary
- Emphasize that discontinuation due to weight concerns is not supported by objective data
- Consider Zoely an excellent option for women seeking effective contraception without metabolic concerns
For overweight/obese patients:
- Zoely remains highly effective in this population 1
- No evidence suggests reduced efficacy or increased weight gain in higher BMI patients using this formulation
The evidence consistently demonstrates that concerns about weight gain should not deter initiation or continuation of Zoely, as this is a weight-neutral contraceptive option with excellent clinical tolerance 7.